Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE versus IGALMI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE versus IGALMI.
BRIMONIDINE TARTRATE vs IGALMI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces aqueous humor production and increases uveoscleral outflow by activating presynaptic alpha-2 receptors, inhibiting norepinephrine release and decreasing cAMP in ciliary epithelium.
Selective alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the central nervous system, resulting in decreased agitation and sedation.
1 drop of 0.1% or 0.15% solution in the affected eye(s) twice daily, approximately 12 hours apart.
Sublingual: 120 mcg to 180 mcg as a single dose, administered under the tongue, one time. Maximum single dose: 180 mcg.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in adults; in neonates and infants, half-life may be prolonged (up to 8–12 hours) due to immature renal function.
Terminal elimination half-life is 2.5 to 3.5 hours in healthy subjects, with prolonged half-life in patients with hepatic impairment (up to 5-7 hours) or renal impairment (up to 6-8 hours).
Renal excretion of unchanged drug and metabolites accounts for approximately 74% of the dose; fecal excretion accounts for approximately 22%. The remainder is eliminated via biliary secretion.
Approximately 75% of the dose is excreted renally as unchanged drug, with the remainder eliminated via biliary/fecal routes (approximately 20%) and minor metabolic clearance.
Category A/B
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist